Scarica l'app Stockscreener
10.31
0.98%
0.10
Dopo l'orario di chiusura:
10.39
0.08
+0.78%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.21
Aprire:
$10.34
Volume 24 ore:
1.72M
Relative Volume:
1.43
Capitalizzazione di mercato:
$1.10B
Reddito:
-
Utile/perdita netta:
$-249.31M
Rapporto P/E:
-3.5923
EPS:
-2.87
Flusso di cassa netto:
$-209.70M
1 W Prestazione:
-7.45%
1M Prestazione:
-13.51%
6M Prestazione:
-56.30%
1 anno Prestazione:
-62.22%
Intervallo 1D:
$10.14
$10.61
Intervallo di 1 settimana:
$10.12
$11.24
Portata 52W:
$10.12
$31.47
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Nome
Rocket Pharmaceuticals Inc
Settore
Industria
Telefono
646-440-9100
Indirizzo
350 FIFTH AVENUE, NEW YORK, NY
Confronta RCKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
10.31 | 1.10B | 0 | -249.31M | -209.70M | -2.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | Wedbush | Outperform |
| 2024-12-18 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Iniziato | Morgan Stanley | Overweight |
| 2022-11-08 | Iniziato | Canaccord Genuity | Buy |
| 2022-11-01 | Iniziato | BTIG Research | Buy |
| 2022-07-08 | Iniziato | Raymond James | Outperform |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2021-02-18 | Iniziato | Needham | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Iniziato | JP Morgan | Overweight |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2019-11-06 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-26 | Iniziato | Piper Jaffray | Overweight |
| 2019-04-23 | Iniziato | Robert W. Baird | Outperform |
| 2019-03-15 | Iniziato | BofA/Merrill | Buy |
| 2019-02-05 | Iniziato | Oppenheimer | Outperform |
| 2018-09-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-07-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month Low – Time to Sell? - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 4%Here's Why - MarketBeat
How to Take Advantage of moves in (RCKT) - Stock Traders Daily
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's Why - MarketBeat
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Mirador Capital Partners LP - MarketBeat
JPMorgan Chase & Co. Decreases Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 12-Month LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.9%Time to Buy? - MarketBeat
Learn to Evaluate (RCKT) using the Charts - Stock Traders Daily
RCKTRocket Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Q4 Earnings Estimate for RCKT Issued By Wedbush - Defense World
Brokers Set Expectations for RCKT Q4 Earnings - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading 3.7% HigherWhat's Next? - MarketBeat
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’ - Yahoo Finance
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at Wedbush - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth - Investing.com Canada
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Wedbush - MarketBeat
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
(RCKT) On The My Stocks Page - Stock Traders Daily
Geode Capital Management LLC Boosts Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Position Decreased by HighTower Advisors LLC - Defense World
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year LowHere's Why - MarketBeat
State Street Corp Buys 322,156 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Franklin Resources Inc. Cuts Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
State Street Corp Has $57.29 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpShould You Buy? - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Jefferies Financial Group - MarketBeat
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
RTW INVESTMENTS, LP Increases Stake in Rocket Pharmaceuticals Inc - GuruFocus.com
(RCKT) Trading Report - Stock Traders Daily
Synovus Financial Corp Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Leerink Partnrs Has Positive Outlook of RCKT FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for RCKT Issued By Leerink Partnrs - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com Australia
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 1-Year LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals completes $178.1 million offering - Investing.com India
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - MSN
Rocket Pharmaceuticals completes $178.1 million offering By Investing.com - Investing.com Australia
RSI Alert: Rocket Pharmaceuticals (RCKT) Now Oversold - Nasdaq
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges - Investing.com India
RCKT Stock Hits 52-Week Low at $12.62 Amid Market Challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals Inc Azioni (RCKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rocket Pharmaceuticals Inc Azioni (RCKT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Kinnari | See Remarks |
Nov 21 '24 |
Sale |
13.05 |
4,588 |
59,892 |
392,395 |
| Shah Gaurav | CEO |
Nov 21 '24 |
Sale |
13.05 |
11,091 |
144,782 |
707,328 |
| Wilson Martin | General Counsel |
Nov 21 '24 |
Sale |
13.05 |
1,175 |
15,338 |
63,560 |
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):